Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unresectable tumors can be difficult to manage. Until recently, no approved systemic therapy was available for locally advanced or metastatic BCC inappropriate for surgery or radiotherapy. Vismodegib provides a systemic treatment option. However, a consensus definition of advanced BCC is lacking. A multidisciplinary panel with expertise in oncology, dermatology, dermatologic surgery and radiation oncology proposes a consensus definition based on published evidence and clinical experience.

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: An expert panel consensus / Peris, K.; Licitra, L.; Ascierto, P. A.; Corvo, R.; Simonacci, M.; Picciotto, F.; Gualdi, G.; Pellacani, G.; Santoro, A.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:4(2015), pp. 703-712. [10.2217/fon.14.281]

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: An expert panel consensus

Gualdi G.;Pellacani G.;
2015

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for the majority of high-risk lesions. Aggressive, recurrent or unresectable tumors can be difficult to manage. Until recently, no approved systemic therapy was available for locally advanced or metastatic BCC inappropriate for surgery or radiotherapy. Vismodegib provides a systemic treatment option. However, a consensus definition of advanced BCC is lacking. A multidisciplinary panel with expertise in oncology, dermatology, dermatologic surgery and radiation oncology proposes a consensus definition based on published evidence and clinical experience.
2015
11
4
703
712
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: An expert panel consensus / Peris, K.; Licitra, L.; Ascierto, P. A.; Corvo, R.; Simonacci, M.; Picciotto, F.; Gualdi, G.; Pellacani, G.; Santoro, A.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:4(2015), pp. 703-712. [10.2217/fon.14.281]
Peris, K.; Licitra, L.; Ascierto, P. A.; Corvo, R.; Simonacci, M.; Picciotto, F.; Gualdi, G.; Pellacani, G.; Santoro, A.
File in questo prodotto:
File Dimensione Formato  
peris2015.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 2.46 MB
Formato Adobe PDF
2.46 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1183240
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 42
social impact